[{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TerSera Presents Data on cetirizine HCL Injection for Hypersensitivity Infusion Reactions in Breast Cancer and Other Malignancies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TerSera\u00ae Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo\u00ae (telotristat ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase IV"},{"orgOrder":0,"company":"TerSera Canada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves ZOLADEX\u00ae LA for the Management of Estrogen Receptor-Positive (ER+) Early Breast Cancer with a High Risk of Recurrence or Advanced Breast Cancer in Pre- and Perimenopausal Women","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase IV","country":"CANADA","productType":"Peptide","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by TerSera Therapeutics
Health Canada has approved a sNDA for ZOLADEX LA (goserelin acetate), GnRH agonist at 10.8mg every 12 weeks for the management of ER+ early breast cancer in pre- and perimenopausal women.
Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
First randomized, double-blind, controlled trial evaluating IV cetirizine versus IV diphenhydramine in the prevention of hypersensitivity infusion reactions. QUZYTTIR is the first and only injectable second-generation H1 antihistamine to be approved by the U.S. FDA.